Medication info
Gabapentin Tablet 25 mg (Pregabalin)

Gabapentin Tablet 25 mg (Pregabalin)

Prescription medicationTabletOral
Ingredient · strength
Pregabalin›25mg / 1 tablet
Manufacturer / importer
Samil Pharmaceutical Co., Ltd.
Appearance
Pink round tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201905358 · Approved 2019.07.29 · Insurance code 643903710

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Neuropathic pain—Peripheral neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. Neuropathic pain—Central neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy: Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. Fibromyalgia: The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. No dose adjustment is necessary in patients with hepatic impairment. Older adults (65 years and older): Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Samil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to alleviate peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures in patients with epilepsy, either with or without secondary generalized symptoms. Additionally, it is effective in treating fibromyalgia. This helps improve symptoms related to various nerve-related disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Neuropathic pain—Peripheral neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. Neuropathic pain—Central neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy: Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. Fibromyalgia: The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. No dose adjustment is necessary in patients with hepatic impairment. Older adults (65 years and older): Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so it is crucial to closely monitor for mood changes, abnormal behavior, or symptoms of depression during treatment. Individuals allergic to any component of this medication should not take it. Diabetic patients may be affected in blood glucose control due to weight gain, and dosage adjustment of antidiabetic medications may be necessary. If symptoms of angioedema occur, discontinue the medication immediately and consult a healthcare provider. Elderly patients should be particularly careful when taking this medication initially due to the risk of dizziness or drowsiness that may lead to falls. Temporary blurring of vision or changes in vision may occur, and if symptoms are severe, discontinuation of the medication may be necessary. Caution is required when transitioning from other antiepileptic drugs to monotherapy. Abrupt discontinuation of the medication may cause withdrawal symptoms such as insomnia, headaches, nausea, and anxiety, so consultation with a healthcare provider is necessary. There is a potential for drug abuse or dependence, so patients with a history of substance abuse should be especially careful. Patients with impaired renal function may require dose adjustments. Patients with heart failure should be cautious when taking this medication. Combining with central nervous system depressants may pose a risk of respiratory depression, so caution is advised. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant must consult with a healthcare provider before taking this medication. This medication may cause dizziness and drowsiness, necessitating caution while driving or operating machinery. Rarely, severe allergic skin reactions may occur; if skin rash or swelling develops, discontinue use immediately. This medication is mostly excreted through the kidneys, so elderly patients with decreased renal function should have their dosage adjusted. In cases of overdose, symptoms such as drowsiness, confusion, and depression may appear, and treatment such as hemodialysis may be necessary.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, decreased respiratory function, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, depression, euphoria, decreased libido, insomnia, depersonalization, sexual dysfunction, restlessness, anxiety, mood swings, emotional decline, emotional elevation, difficulty in finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to restrain, apathy, ataxia, abnormal limb coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonus, decreased reflexes, abnormal movements, psychomotor agitation, orthostatic dizziness, sensory hyperreactivity, burning sensation, action tremors, syncope, stupor, motor impairment, olfactory abnormalities, loss of taste, writing impairment, blurred vision, diplopia, visual field loss, visual disturbances, visual field defects, photophobia, dry eyes, ocular swelling, vision loss, eye pain, eye fatigue, increased tear secretion, eye irritation, mydriasis, during vibration, changes in depth perception, strabismus, brightness of vision, dizziness, auditory hypersensitivity, first-degree AV block, tachycardia, bradycardia, tachyarrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, shortness of breath, nasal bleeding, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, joint pain, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle twitching, neck pain, muscle rigidity, rhabdomyolysis, urinary dysfunction, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, peripheral edema, swelling, gait disturbances, falling, feeling of intoxication, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, elevated plasma creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium in the blood, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, shock, anaphylaxis-like symptoms, mucous membrane syndrome, erythema multiforme, delirium, paralysis, affective disorders, drowsiness, confusion state, depression, agitation, restlessness, exacerbation of seizures, gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, blood in stool, fatigue, weakness, gait disturbances, decreased libido, sleep disorders, insomnia, ataxia, speech difficulties, sensory abnormalities, memory disorders, attention disorders, constipation, gastrointestinal disorders, blood in stool, increased BUN, urinary incontinence, difficulty urinating, erectile dysfunction.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a closed container to protect it from air and moisture. Additionally, it is best to store the medication at room temperature between 1°C and 30°C. This helps maintain the medication's efficacy for an extended period.

Appearance and packaging

Appearance

Pink round tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.